Citations

Showing 10 of 108135 citations.

Women, Mood and Cognition
Files, Julia A. , Kransdorf, Lisa N , Kransdorf, Lisa N.

Mayo Clinic

Journal of Women's Health | August 27, 2021 | Volume: 31 | Issue: 12 | Pages: 1686-1689

10.1089/jwh.2021.0320 | PMID 34448597 Get It

Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma
Orellana‐Noia, Victor M. , Isaac, Krista M. , Malecek, Mary‐Kate , Bartlett, Nancy L. , Voorhees, Timothy , Grover, Natalie S. , Hwang, Steven R. , Bennani, N. Nora , Hu, Rachel , Hill, Brian T. , Mou, Eric , Advani, Ranjana H. , Carter, Jordan , David, Kevin A. , Ballard, Hatcher J. , Svoboda, Jakub , Churnetski, Michael C. , Magarelli, Gabriela, Feldman, Tatyana , Cohen, Jonathon B. , Evens, Andrew M. , Portell, Craig A. , Isaac, Krista , Voorhees, Timothy J , Cohen, Jonathon B , Bartlett, Nancy L , Advani, Ranjana H , Bennani, N Nora , Evens, Andrew M , Grover, Natalie S , Hwang, Steven R , Portell, Craig A , Mou, Eric

Mayo Clinic

Blood Advances | August 27, 2021 | Volume: 5 | Issue: 18 | Pages: 3623-3632

10.1182/bloodadvances.2021004645 | PMID 34448831 Get It

Abstract We performed a multicenter retrospective analysis across 10 US academic medical centers to evaluate treatment patterns and outcomes in patients age ≥60 years with classic Hodgkin lymphoma (cHL) from 2010-2018. Among 244 eligible patients, median age was 68, 63% had advanced stage (III/IV), 96% had Eastern Cooperative Oncology Group performance status (PS) 0-2, and 12% had documented loss of ≥1 activity of daily living (ADL). Medical comorbidities were assessed by the Cumulative Illness Rating Scale–Geriatric (CIRS-G), where n = 44 (18%) had total scores ≥10. Using multivariable Cox models, only ADL loss predicted shorter progression-free (PFS; hazard ratio [HR] 2.13, P = .007) and overall survival (OS; HR 2.52, P = .02). Most patients (n = 203, 83%) received conventional chemotherapy regimens, including doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD; 56%), AVD (14%), and AVD with brentuximab vedotin (BV; 9%). Compared to alternative therapies, conventional regimens significantly improved PFS (HR 0.46, P = .0007) and OS (HR 0.31, P = .0003). Survival was similar following conventional chemotherapy in those ages 60-69 vs ≥70: PFS HR 0.88, P = .63; OS HR 0.73, P = .55. Early treatment discontinuation due to toxicity was more common with CIRS-G ≥10 (28% vs 12%, P = .016) or documented geriatric syndrome (28% vs 13%, P = .02). A competing risk analysis demonstrated improved disease-related survival with conventional therapy (HR 0.29, P = .02) and higher mortality from causes other than disease or treatment with high CIRS-G or geriatric syndromes. This study suggests conventional chemotherapy regimens remain a standard of care in fit older patients with cHL, and highlights the importance of geriatric assessments in defining fitness for cHL therapy going forward.
Posterior fusion for fragility type 2 odontoid fractures
Traynelis, Vincent C. , Fontes, Ricardo B. V. , Cox, Efrem M., Abode-Iyamah, Kingsley O., Abode-Iyamah, Kingsley , Greenlee, Jeremy D.W.

Mayo Clinic

Journal of Neurosurgery: Spine | August 27, 2021 | Volume: 35 | Issue: 5 | Pages: 644-650

10.3171/2021.2.spine201645 | PMID 34388709 Get It

OBJECTIVE The purpose of this study was to evaluate the outcomes of elderly patients with type 2 odontoid fractures treated with an instrumented posterior fusion. METHODS Ninety-three consecutive patients older than 65 years of age in whom a type 2 odontoid fracture had been treated with a variety of C1–2 posterior screw fixation techniques were retrospectively reviewed. RESULTS The average age was 78 years (range 65–95 years). Thirty-seven patients had an additional fracture, 30 of which involved C1. Three patients had cervical spinal cord dysfunction due to their injury. All patients had comorbidities. The average total hospitalization was 9.6 days (range 2–37 days). There were 3 deaths and 19 major complications, the most common of which was pneumonia. No patient suffered a vertebral artery injury. Imaging studies were obtained in 64 patients at least 12 months postsurgery (mean 19 months). Fusion was assessed by dynamic radiographs in all cases and with a CT scan in 80% of the cases. Four of the 64 patients did not achieve fusion (6.25% overall). All patients in whom fusion failed had undergone C1 lateral mass fixation and C2 pars (1/29, 3.4%) or laminar (3/9, 33.3%) fixation. CONCLUSIONS Instrumented posterior cervical fusions may be performed in elderly patients with acceptable morbidity and mortality. The fusion rate is excellent except when bilateral C2 translaminar screws are used for axis fixation.
Reply to Krishna and Jain
Al‐Haddad, Mohammad , Wallace, Michael B. , Wallace, Michael B , Al-Haddad, Mohammad

Mayo Clinic

Endoscopy | August 26, 2021 | Volume: 53 | Issue: 09 | Pages: 988-988

10.1055/a-1473-5567 | PMID 34438462 Get It

As far as the AI can see
Leggett, Cadman L. , Katzka, David A. , Leggett, Cadman L

Mayo Clinic

Endoscopy | August 26, 2021 | Volume: 53 | Issue: 09 | Pages: 884-885

10.1055/a-1352-4811 | PMID 34438451 Get It

Bromodomain containing 9 (BRD9) regulates macrophage inflammatory responses by potentiating glucocorticoid receptor activity
Wang, Liu , Oh, Tae Gyu , Magida, Jason A. , Estepa, Gabriela , Obayomi, S. M. Bukola , Yu, Ruth T. , Atkins, Annette R. , Hargreaves, Diana C. , Downes, Michael , Wei, Zong , Magida, Jason , Chong, Ling-Wa , Gatchalian, Jovylyn , Yu, Ruth T , Atkins, Annette R , Hargreaves, Diana , Downes, Michael , Wei, Zong , Evans, Ronald M , Evans, Ronald M.

Mayo Clinic

Proceedings of the National Academy of Sciences | August 26, 2021 | Volume: 118 | Issue: 35 | Pages: No page available

10.1073/pnas.2109517118 | PMID 34446564 Get It

Significance Glucocorticoids are widely prescribed antiinflammatory drugs that suppress inflammatory gene expression through activation of the glucocorticoid receptor (GR); however, the mechanisms of GR-mediated repression are not fully understood. We show here that bromodomain containing 9 (BRD9), a component of the SWI/SNF chromatin remodeling complex, modulates GR activity in bone marrow-derived macrophages. Loss of BRD9 activity in macrophages attenuated the response to liposaccharides and interferon inflammatory stimuli. Notably, BRD9 inhibition synergized with the synthetic glucocorticoid dexamethasone to suppress the inflammatory response in macrophages. Our data support a model in which BRD9 restricts GR binding at a subset of inflammatory related genes, and suggests that BRD9 inhibitors may increase the efficacy of glucocorticoids.
Orthopaedic Gene Therapy
Evans, Christopher H. , Ghivizzani, Steve, Robbins, Paul D. , Robbins, Paul D

Mayo Clinic

JBJS Reviews | August 26, 2021 | Volume: 9 | Issue: 8 | Pages: No page available

10.2106/jbjs.rvw.20.00220 | PMID 34437305 Get It

» Orthopaedics pioneered the expansion of gene therapy beyond its traditional scope of diseases that are caused by rare single-gene defects. Orthopaedic applications of gene therapy are most developed in the areas of arthritis and regenerative medicine, but several additional possibilities exist. » Invossa, an ex vivo gene therapeutic for osteoarthritis, was approved in South Korea in 2017, but its approval was retracted in 2019 and remains under appeal; a Phase-III clinical trial of Invossa has restarted in the U.S. » There are several additional clinical trials for osteoarthritis and rheumatoid arthritis that could lead to approved gene therapeutics for arthritis. » Bone-healing and cartilage repair are additional areas that are attracting considerable research; intervertebral disc degeneration and the healing of ligaments, tendons, and menisci are other applications of interest. Orthopaedic tumors, genetic diseases, and aseptic loosening are additional potential targets. » If successful, these endeavors will expand the scope of gene therapy from providing expensive medicines for a few patients to providing affordable medicines for many.
Multi‐omic molecular profiling guide’s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial
Pierobon, Mariaelena , Robert, Nicholas J. , Northfelt, Donald W. , Jahanzeb, Mohammad , Wong, Shukmei , Hodge, Kimberly A., Baldelli, Elisa , Aldrich, Jessica, Craig, David W. , Liotta, Lance A. , Avramovic, Sanja , Wulfkuhle, Julia , Bellos, Angela, Gallagher, Rosa I. , Arguello, David, Conrad, Amber, Kemkes, Ariane, Loesch, David, Vocila, Linda, Dunetz, Bryant, Carpten, John D. , Petricoin, Emanuel F. , Anthony, Stephen P. , Gallagher, Rosa I , Wojtusiak, Janusz , Alemi, Farrokh

Mayo Clinic

Molecular Oncology | August 26, 2021 | Volume: 16 | Issue: 1 | Pages: 104-115

10.1002/1878-0261.13091 | PMID 34437759 Get It

This prospective phase II clinical trial (Side Out 2) explored the clinical benefits of treatment selection informed by multi‐omic molecular profiling (MoMP) in refractory metastatic breast cancers (MBCs). Core needle biopsies were collected from 32 patients with MBC at trial enrollment. Patients had received an average of 3.94 previous lines of treatment in the metastatic setting before enrollment in this study. Samples underwent MoMP, including exome sequencing, RNA sequencing (RNA‐Seq), immunohistochemistry, and quantitative protein pathway activation mapping by Reverse Phase Protein Microarray (RPPA). Clinical benefit was assessed using the previously published growth modulation index (GMI) under the hypothesis that MoMP‐selected therapy would warrant further investigation for GMI ≥ 1.3 in ≥ 35% of the patients. Of the 32 patients enrolled, 29 received treatment based on their MoMP and 25 met the follow‐up criteria established by the trial protocol. Molecular information was delivered to the tumor board in a median time frame of 14 days (11–22 days), and targetable alterations for commercially available agents were found in 23/25 patients (92%). Of the 25 patients, 14 (56%) reached GMI ≥ 1.3. A high level of DNA topoisomerase I (TOPO1) led to the selection of irinotecan‐based treatments in 48% (12/25) of the patients. A pooled analysis suggested clinical benefit in patients with high TOPO1 expression receiving irinotecan‐based regimens (GMI ≥ 1.3 in 66.7% of cases). These results confirmed previous observations that MoMP increases the frequency of identifiable actionable alterations (92% of patients). The MoMP proposed allows the identification of biomarkers that are frequently expressed in MBCs and the evaluation of their role as predictors of response to commercially available agents. Lastly, this study confirmed the role of MoMP for informing treatment selection in refractory MBC patients: more than half of the enrolled patients reached a GMI ≥ 1.3 even after multiple lines of previous therapies for metastatic disease.
Cardiac MRI for Left Ventricular Dyssynchrony: Time for Coordinated Response
Rajiah, Prabhakar , François, Christopher J. , Rajiah, Prabhakar , François, Christopher

Mayo Clinic

Radiology: Cardiothoracic Imaging | August 26, 2021 | Volume: 3 | Issue: 4 | Pages: e210193

10.1148/ryct.2021210193 | PMID 34498012 Get It